Abstract
Longitudinal studies with very long follow–up periods of patients with obsessive–compulsive disorder (OCD) who have received adequate treatment are rare. In the current study, 30 of 37 inpatients (81%) with severe OCD were followed up 6–8 years after treatment with cognitive–behavioral therapy (CBT) in combination with either fluvoxamine or placebo in a randomized design. The significant improvements (with large effectsizes) in obsessive–compulsive symptoms from pre- to post–treatment (41% reduction on the Y–BOCS) remained stable at follow–up (45 %). Responder rates, defined as ≥35% reduction on the Y–BOCS, were 67% and 60%, respectively. Depressive symptoms decreased significantly not only from pre- to post–treatment but also during follow–up. Re–hospitalization, which occurred in 11 patients (37 %), was associated with more severe depressive symptoms at pre–treatment and living without a partner. Full symptom remission at follow–up, defined as both Y–BOCS total score ≤ 7 and no longer meeting diagnostic criteria for OCD, was achieved by 8 patients (27 %). Patients without full remission at follow–up had a significantly longer history of OCD, assessed at pretreatment, compared to remitted patients. The shortterm treatment outcome had no predictive value for the long–term course. Throughout the naturalistic follow–up, nearly all patients (29 patients) received additional psychotherapy and/or medication. This might indicate that such chronic OCD patients usually need additional therapeutic support after effective inpatient treatment to maintain their improvements over long periods.
Similar content being viewed by others
References
Alonso P, Menchon JM, Pifarre J, Mataix Cols D, Torres L, Salgado P, Vallejo J (2001) Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 62:535–540
Ballenger JC (1999) Current treatments of the anxiety disorders in adults. Biol Psychiatry 46:1579–1594
Basoglu M, Lax T, Kasvikis Y, Marks IM (1988) Predictors of improvement in obsessive-compulsive disorder. J Anxiety Disord 2:299–317
Bobes J, González MP, Bascarán MT, Arango C, Sáiz PA, Bousono M (2001) Quality of life and disability in patients with obsessivecompulsive disorder. European Psychiatry 16:239–245
Bouvard MA, Milliery M, Cottraux J (2004) Management of obsessive compulsive disorder. Psychother Psychosom 73:149–157
Büttner-Westphal H, Hand I (1991) Yale-Brown Obsessive-Compulsive Scale (Y-BOCS),deutsche Übersetzung und Bearbeitung. Verhaltenstherapie 1:226–233
CIPS (1990) Internationale Skalen für Psychiatrie. Beltz, Weinheim
Cottraux J, Mollard E, Bouvard M, Marks I (1992) Exposure therapy, Fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 49:63–75
Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, Douge R, Cialdella P (1990) A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 5:17–30
Doyle AC, Pollack MH (2003) Establishment of Remission Criteria for Anxiety Disorders. J Clin Psychiatry 64:40–45
Foa EB (1979) Failure in treating obsessive-compulsives. Behavior Research and Therapy 17:169–176
Foa EB, Grayson JB, Steketee G, Doppelt HG, Turner RM, Latimer PR (1983) Success and failure in the behavioral treatment of obsessive- compulsives. J Consult Clin Psychol 51:287–297
Fricke S, Moritz B, Andresen B, Hand I, Jacobsen M, Kloss M, Rufer M (2003) Einfluss von Persönlichkeitsstörungen auf den Erfolg einer multimodalen Verhaltenstherapie bei Zwangserkrankungen – Teil II: Ergebnisse einer empirischen Studie. Verhaltenstherapie 13:172–182
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive Compulsive Scale. II.Validity. Arch Gen Psychiatry 46:1012–1016
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive-Compulsive Scale. I.Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011
Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U (2001) Lifetime-comorbidity of obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany. Eur Arch Psychiatry Clin Neurosci 251:130–135
Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U (2000) Prevalence, quality of life and psychosocial functioning in obsessive-compulsive disorder and subclinical obsessive- compulsive disorder in northern Germany. Eur Arch Psychiatry Clin Neurosci 250:262–268
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Hand I (2000) Group exposure in vivo for agoraphobics (1974): a multifaceted pilot study and its impact on subsequent agoraphobia research. Behav Cogn Psychother 28:335–351
Hand I (1998) Out-patient, multimodal behaviour therapy for obsessive-compulsive disorder. Br J Psychiatry 173:45–52
Hand I, Peter H, Rufer M (2001) Kombinationsbehandlung mit Verhaltenstherapie und Pharmakotherapie bei Zwangsstörungen. Verhaltenstherapie 11:206–216
Hohagen F, Winkelmann G, Rasche-Räuchle H, Hand I, Münchau N, Hiss H, Geiger-Kabisch C, Käppler P, Schramm P, Rey E, Aldenhoff J, Berger M (1998) Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo.Results of a multicentre study. Br J Psychiatry 173:71–78
Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224–231
Leonard HL, Swedo SE, Lenane MC, Rettew DC, Cheslow DL, Hamburger SD, Rapoport JL (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48:922–927
Marks IM (1997) Behaviour therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry 42:1021–1027
Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 136:1–25
Masellis M, Rector NA, Richter MA (2003) Quality of life in OCD: Differential impact of obsessions, compulsions, and depression comorbidity. Can J Psychiatry 48:72–77
Mawson D, Marks IM, Ramm L (1982) Clomipramine and exposure for chronic obsessive-compulsive rituals: Two year followup and further findings. Br J Psychiatry 140:11–18
Moritz S, Fricke S, Jacobsen D, Kloss M, Wein C, Rufer M, Katenkamp B, Farhumand R, Hand I (2004) Positive schizotypical symptoms predict treatment outcome in obsessive-compulsive disorder. Behav Res Ther 42:217–227
Moritz S, Meier B, Hand I, Schick M, Jahn H (2004) Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder. Psychiatry Res 125:171–180
Nierenberg AA, DeCecco LM (2001) Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry 62:16
O’Sullivan G, Noshirvani H, Marks IM,WM, Lelliott P (1991) Sixyear follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry 52:150–155
Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145:1521–1525
Perugi G, Akiskal HS, Pfanner C, Presta S, Milanfranchi A, Lensi P, Ravagli S, Maremmani I, Cassano GB (1998) Episodic course in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 248:240–244
Rufer M, Hand I, Braatz A, Alsleben H, Fricke S, Peter H (2004) A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy. Psychother Psychosom 73:101–106
Ruhmland M, Margraf J (2001) Effektivität psychologischer Therapien von spezifischer Phobie und Zwangsstörung: Meta- Analysen auf Störungsebene. Verhaltenstherapie 11:14–26
Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232–241
Skoog G, Skoog I (1999) A 40-year follow-up of patients with obsessive- compulsive disorder. Arch Gen Psychiatry 56:121–127
Spitzer RL, Williams JB, Gibbsons M (1984) The Structured Clinical Interview for DSM-III-R, New York: New York State Psychiatric Institute, Biometric Research Department
Steketee G (1993) Social support and treatment outcome of obsessive compulsive disorder at 9-month follow-up. Behav Psychother 21:81–95
Steketee G, Chambless DL, Tran GQ (2001) Effects of axis I and II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. Compr Psychiatry 42:76–86
Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S (1999) Predictors of course in obsessive-compulsive disorder. Psychiatry Res 89:229–238
Steketee G, Shapiro LJ (1995) Predicting behavioral treatment outcome for agoraphobia and obsessive compulsive disorder. Clin Psychol Rev 15:317–346
Wittchen HU, Zaudig M, Schramm E, Spengler P (1988) Strukturiertes klinisches Interview für DSM-III-R (SKID), Weinheim: Beltz
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rufer, M., Hand, I., Alsleben, H. et al. Long–term course and outcome of obsessive–compulsive patients after cognitive–behavioral therapy in combination with either fluvoxamine or placebo. Eur Arch Psychiatry Clin Neurosci 255, 121–128 (2005). https://doi.org/10.1007/s00406-004-0544-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-004-0544-8